There are 2949 resources available
686P - Macrophage composition as a prognostic indicator of time to progression and radiotherapy response in prostate adenocarcinoma
Presenter: Neil Jairath
Session: E-Poster Display
Resources:
Abstract
687TiP - ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer
Presenter: Sumit Subudhi
Session: E-Poster Display
Resources:
Abstract
688TiP - Genetic information to inform treatment and screening (GIFTS) study for prostate cancer: Characterizing germline DNA alterations in men with metastatic prostate cancer and their first-degree male relatives
Presenter: Risa Wong
Session: E-Poster Display
Resources:
Abstract
689TiP - NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
Presenter: Zachary Zumsteg
Session: E-Poster Display
Resources:
Abstract
690TiP - A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)
Presenter: Charles Drake
Session: E-Poster Display
Resources:
Abstract
691TiP - A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status
Presenter: Ugo De Giorgi
Session: E-Poster Display
Resources:
Abstract
692TiP - BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Carlo Cattrini
Session: E-Poster Display
Resources:
Abstract
693TiP - LOBSTER LOng term Better than Short-TErm ADT with salvage radiotherapy
Presenter: Charlien Berghen
Session: E-Poster Display
Resources:
Abstract
694TiP - DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Presenter: Tamim Niazi
Session: E-Poster Display
Resources:
Abstract
695TiP - ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region)
Presenter: Joan Carles
Session: E-Poster Display
Resources:
Abstract